Swiss HIV Cohort Study

Avery et al., Leukozytenzahl und Risiko für Herzkreislaufereignisse

Leukozytenzahl und Risiko für Herzkreislaufereignisse: Eine longitudinale Analyse bei den Teilnehmern der Schweizerischen HIV-Kohortenstudie. Clinical Infectious Disease Menschen mit HIV haben im Vergleich zur allgemeinen Population ein höheres Risiko, ein Herzkreislaufereignis zu erleiden. Dieses Risiko hängt insbesondere mit dem Vorhandensein klassischer Risikofaktoren für Herzkreislauferkrankungen (Rauchen, Bewegungsmangel, hoher Cholesterinspiegel, Diabetes, Bluthochdruck, Adipositas, Familiengeschichte), aber auch mit […]

Lanz et al., HIV low-level viremia predicts viral failure

Lanz et al. aimed to investigate the impact and clinical significance of low-level viremia (LLV), accounting for its dynamic nature on the highly granular longitudinal data set from the SHCS spanning >2 decades, enabling a detailed and dynamic assessment of LLV without relying on aggregated or cumulative data. The authors analysed participants in the Swiss […]

Roen et al., cLEE and use of contemporary ARVs among PWH

Chronic liver enzyme elevation and use of contemporary ARVs among persons living with HIV.   Open Forum Infectious Diseases Roen et al. on behalf of the RESPOND consortium aimed to identify risk factors associated with chronic liver enzyme (transaminase) elevation (cLEE), focusing on commonly prescribed antiretrovirals (ARVs) in RESPOND, namely INSTIs (dolutegravir [DTG], raltegravir [RAL], […]

Fernbach et al., Development and consequences of IFN-I autoAbs

Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies.   Journal of Experimental Medicine Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. In this work, the authors traced the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year […]

Amstutz et al., Bivalent SARS-CoV-2 vaccines

Antibody and T-Cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function: COVERALL-3 Study.   Journal of Infectious Diseases. Vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevented severe disease, including among immunocompromised individuals. Over the course of the pandemic, bivalent vaccines were developed to improve vaccine effectiveness against emerging variants. […]

Abela et al., SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study

Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study.   Journal of Infectious Diseases. Abela et al. aimed to explore the epidemiology of SARS-CoV-2 waves in Switzerland from 2020–2021 among people with HIV (PWH) compared with the general Swiss population and determined the parameters associated with SARS-CoV-2 infection in both populations. The author […]

Paioni et al., Cohort profile: the Swiss Mother and Child HIV Cohort Study (MoCHiV)

Cohort profile: the Swiss Mother and Child HIV Cohort Study (MoCHiV).   BMJ Open The prevention of vertical transmission, as well as the improvement of pregnancy care, are key to delivering optimal care for people with HIV. In collaboration with the Swiss HIV Cohort Study, the Swiss Mother and Child HIV Cohort Study (MoCHiV) collects longitudinal […]

Marinosci et al., Efficacy and safety of DTG + FTC vs cART for the maintenance of HIV suppression

Efficacy and safety of dolutegravir plus emtricitabine vs combined antiretroviral therapy for the maintenance of HIV suppression: results through week 144 of the SIMPL’HIV trial.   Open Forum Infectious Diseases The SIMPL’HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression. The study found […]

Thoueille et al., Concentrations résiduelles et efficacité dans la vie réelle du cabotégravir et de la rilpivirine à action prolongée

Concentrations résiduelles et efficacité dans la vie réelle du cabotégravir et de la rilpivirine à action prolongée: une étude observationnelle prospective multicentrique en Suisse.   The Lancet Regional Health – Europe. La façon de traiter le VIH a beaucoup progressé ces dernières années, avec l’arrivée de nouveaux médicaments comme le cabotégravir et la rilpivirine à action […]

Thoueille et al., Concentrazioni residue di cabotegravir e rilpivirina a lunga durata d’azione ed efficacia nella vita reale

Concentrazioni residue di cabotegravir e rilpivirina a lunga durata d’azione ed efficacia nella vita reale: Studio osservazionale prospettico multicentrico in Svizzera. The Lancet Regional Health – Europe. La modalità di trattamento dell’infezione HIV è migliorata notevolmente negli ultimi anni, in particolare con l’arrivo di farmaci ad azione prolungata come la combinazione cabotegravir e rilpivirina somministrati tramite […]